Fig. 1From: Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective studyParticipant disposition. AE, adverse event. aParticipants who received at least 1 dose of study treatment after enrollment. bExcludes participants who had no efficacy data at least 15Â days after the start of study treatmentBack to article page